Phase 3 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are at least 12 years old at the time of signing the consent form
- You have been diagnosed with atopic dermatitis (eczema) for at least 1 year, based on standard medical guidelines
- You have previously tried a biologic medication or a JAK inhibitor pill for atopic dermatitis and it did not work well enough
- Your eczema is rated as moderate to severe (a score of 3 or 4) by a doctor at the start of the trial
- Your eczema severity score (called EASI) is 16 or higher at the start of the trial
- Your eczema covers 10% or more of your body surface area at the start of the trial
- Your itch, measured by a daily score averaged over a week, is rated 4 or higher at the start of the trial
- You are able and willing to attend required study visits and follow study procedures
- You weigh at least 25 kg (approximately 55 lbs)
Who may not be able to join:
- You have another skin condition that would make it difficult to assess your eczema properly
- You have a known or suspected condition that significantly weakens your immune system
- You have or have had any form of cancer, except for a certain type of non-melanoma skin cancer that was fully removed and cured more than 5 years ago
- You have previously had a solid organ transplant (such as a kidney or liver) or a stem cell transplant
- You currently have an active or ongoing infection, including a parasitic worm infection, that required treatment with medicines taken by mouth or injection within the 4 weeks before the trial starts
- You tested positive for HIV, Hepatitis B, or Hepatitis C at the screening visit
- You have active or latent tuberculosis (TB), a history of TB that was not fully treated, or are considered at high risk of getting TB
- You have received certain specified treatments within specific timeframes before the trial starts (confirm with trial site for the full list)
- You have abnormal lab test results that the investigator considers clinically significant at screening
- You have a known allergy or sensitivity to any ingredient in the study medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 800-633-1610
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36; EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI75) at Week 36; US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.